OIPE JC181
MAR 2 9 2002
PATENT & TRADEMARK OFFICE

A1CO
DAC #6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Inventors: Carl Alexander Kamb, et al.

Serial No: 09/990,912

Filed: November 16, 2001

For: ß-CATENIN ASSAYS, AND COMPOSITIONS THEREFROM

Group Art Unit:
Examiner:

Certificate of Mailing/Transmission(37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is, on the date shown below, being:

MAILING

[X] deposited with the United States Postal Service as First Class Mail on the date indicated below in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231

FACSIMILE

[] transmitted by facsimile to the Patent and Trademark Office

Date: March 18, 2002

Type or Print Name of Person Mailing: Joan Karr

Signature of Person Mailing

RESPONSE TRANSMITTAL LETTER

Assistant Commissioner for Patents
Washington, D. C. 20231

RECEIVED
APR 0 3 2002
OFFICE OF PETITIONS

Sir:

Enclosed herewith for filing are the following:

_____ Response to Restriction Requirement Under 37 U.S.C. § 121.
_____ Preliminary Amendment Under 37 C.F.R. § 1.115.
_____ Amendment and Response Under 37 C.F.R. § 1.111.
_____ Revocation of Power of Attorney and Appointment of New Attorney
_____ Amendment after Final Action Under 37 C.F.R. § 1.116
_____ Request for Extension of Time to File Response Under 37 C.F.R. § 1.136(a).
__X__ Information Disclosure Statement
_____ The Commissioner is hereby authorized to charge Deposit Account No. 501015 in the amount of $_____, calculated as follows:

_____ $55.00/$110.00 for response within first month.
_____ $200.00/$400.00 for response within second month.
_____ $460.00/$920.00 for response within third month.
_____ $720.00/$1,4400.00 for response within fourth month.
_____ Fee for additional claims (see below for calculation).

X The Commissioner is hereby authorized to charge any additional fees which may be required in this application under 37 C.F.R. Sections 1.16-1.17 or to credit any overpayment, to Deposit Account No. 501015. This sheet is filed in duplicate.

Fee-Calculation

Claims:

					Small Entity		OTHER	
					Rate	Fee	Rate	Fee
Basic Fee	Current Claims		Highest Previous			$370.00		$740
Total Claims		-		=	x 9	$	x 18	$
Indep. Claims		-		=	x 42	$	x 84	
Multiple Dependent Claim(s)					+ 140	$	+ 280	$
					TOTAL	$	TOTAL	$

Please address all TELEPHONIC communication to Laura A. Handley, the undersigned attorney of Deltagen Proteomics, Inc. (formerly Arcaris, Inc.) at (801) 303-0304.

Please address all **WRITTEN** correspondence regarding this communication to the following address:

Joseph A. Williams, Jr., Ph.D.
Marshall, Gerstein, & Borun
6300 Sears Tower
233 South Wacker Drive
Chicago, Illinois 60606-6402
(312) 474-6300

Date: March 18, 2002

Respectfully submitted,

By: _____
Laura A. Handley
Registration No. 39,704

Deltagen Proteomics, Inc. (formerly Arcaris, Inc.)
615 Arapeen Drive, Suite 300
Salt Lake City, Utah 84108
Telephone: (801) 303-0300
Telefax: (801) 303-0333

SHEET 1 OF 1

MAR 2 9 2002
PATENT AND TRADEMARK OFFICE

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. VEN009/01	Serial No. US 09/990,912
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Deltagen Proteomics	
		Filing Date 11-16-01	Group

U.S. PATENT DOCUMENTS

*Examiner Initials		Document Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate

RECEIVED
APR 0 3 2002
OFFICE OF PETITIONS

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	Translation No

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SHEET 2 of

PATENT & TRADEMARK OFFICE MAR 29 2002 JC181

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. VEN009/01	Serial No. US 09/990,912
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Deltagen Proteomics	
		Filing Date 11-16-01	Group

FOREIGN PATENT DOCUMENTS

*Examiner Initials		Document Number	Publication Date	Country	Class	Subclass	Translation Yes	Translation No

RECEIVED
APR 03 2002
OFFICE OF PETITIONS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

		Polakis, P. "Wnt signaling and cancer" Genes Dev., *14:* 1837-51, 2000.
		Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., and Kinzler, K. W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC, Science, *275:* 1787-90, 1997.
		Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R., and Birchmeier, W. Functional interaction of beta-catenin with the transcription factor LEF-1, Nature, *382:* 638-42, 1996
		Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., and Clevers, H. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma, Science, *275:* 1784-7, 1997
		Shih, I. M., Yu, J., He, T. C., Vogelstein, B., and Kinzler, K. W. The beta-catenin binding domain of adenomatous polyposis coli is sufficient for tumor suppression, Cancer Res., *60:* 1671-6, 2000.
		Orsulic, S., Huber, O., Aberle, H., Arnold, S., and Kemler, R. E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation, J. Cell Sci., *112:* 1237-45, 1999
		Morin, P. J., Vogelstein, B., and Kinzler, K. W. Apoptosis and APC in

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

OIPE JC#18 MAR 29 2002 PATENT & TRADEMARK OFFICE

Form PTO-1449 (Modified)

U.S. Department of Commerce
Patent and Trademark Office

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Atty. Docket No.	Serial No.
VEN009/01	US 09/990,912
Applicant: Deltagen Proteomics	
Filing Date: 11-16-01	Group:

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

colorectal tumorigenesis, Proc. Natl. Acad. Sci. U S A., *93:* 7950-4, 1996.

Efstathiou, J. A., Liu, D., Wheeler, J. M., Kim, H. C., Beck, N. E., Ilyas, M., Karayiannakis, A. J., Mortensen, N. J., Kmiot, W., Playford, R. J., Pignatelli, M., and Bodmer, W. F. Mutated epithelial cadherin is associated with increased tumorigenicity and loss of adhesion and of responsiveness to the motogenic trefoil factor 2 in colon carcinoma cells, Proc. Natl. Acad. Sci. U S A., *96:* 2316-21, 1999

Miyaki, M., Tanaka, K., Kikuchi-Yanoshita, R., Muraoka, M., Konishi, M., and Takeichi, M. Increased cell-substratum adhesion, and decreased gelatinase secretion and cell growth, induced by E-cadherin transfection of human colon carcinoma cells, Oncogene, *11:* 2547-52, 1995.

Wang, K., Yin, X. M., Chao, D. T., Milliman, C. L., and Korsmeyer, S. J. BID: a novel BH3 domain-only death agonist, Genes Dev., *10:* 2859-69, 1996.

Wheatley, W., Yoo, S., Pierce, M., Rebentisch, M., Endo, M., Peterson, I., Stump, M., McCormack, K., Guzman, M., and Kamb, A. Genetic Selection for Modulators of the MAP Kinase and beta-Catenin Growth-Control Pathways in Mammalian Cells, Submitted for publication

Sawada, S. and Littman, D. R. Identification and characterization of a T-cell-specific enhancer adjacent to the murine CD4 gene, Mol. Cell. Biol., *11:* 5506-15, 1991.

Gradl, D., Kuhl, M., and Wedlich, D. The Wnt/Wg signal transducer beta-catenin controls fibronectin expression, Mol. Cell. Biol., *19:* 5576-87, 1999.

Koshland, D. E., Jr. The era of pathway quantification, Science, *280:* 852-3, 1998

Elson, A. Protein tyrosine phosphatase epsilon increases the risk of mammary hyperplasia and mammary tumors in transgenic mice, Oncogene, *18:* 7535-42, 1999.

Nakayama, T., Ohtsuru, A., Nakao, K., Shima, M., Nakata, K., Watanabe, K., Ishii, N., Kimura, N., and Nagataki, S. Expression in human hepatocellular carcinoma of nucleoside diphosphate kinase, a homologue of the nm23 gene product, J. Natl. Cancer Inst., *84:* 1349-54, 1992.

Graham, F. L., Smiley, J., Russell, W. C., and Nairn, R.

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED
APR 03 2002
OFFICE OF PETITIONS

SHEET 4 of

OIPE JC18
MAR 2 9 2002
PATENT & TRADEMARK OFFICE

Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No. VEN009/01	Serial No. US 09/990,912
INFORMATION DISCLOSURE STATEMENT *(Use several sheets if necessary)*		Applicant Deltagen Proteomics	
		Filing Date 11-16-01	Group

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
		Characteristics of a human cell line transformed by DNA from human adenovirus type 5, J. Gen. Virol., *36:* 59-74, 1977.
		Zhu, A. J. and Watt, F. M. Expression of a dominant negative cadherin mutant inhibits proliferation and stimulates terminal differentiation of human epidermal keratinocytes, J. Cell Sci., *109:* 3013-23, 1996

RECEIVED
APR 0 3 2002
OFFICE OF PETITIONS

EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.